Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Capital Expenditures (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Capital Expenditures for 7 consecutive years, with -$15000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to -$15000.0 in Q4 2025 year-over-year; TTM through Sep 2025 was $20000.0, a N/A change, with the full-year FY2024 number at $1000.0, changed N/A from a year prior.
  • Capital Expenditures was -$15000.0 for Q4 2025 at Soleno Therapeutics, down from $1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9000.0 in Q2 2025 to a low of -$15000.0 in Q4 2025.